Actinium Pharmaceuticals, Inc. ATNM

ATNM Company Overview

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies for hematologic malignancies and certain solid tumor indications. The company operates within the biotechnology and oncology sectors, with a primary emphasis on antibody-radioconjugates and radiotherapy conditioning agents used prior to bone marrow transplantation or cellular therapies. Its core strategy centers on delivering radioactive isotopes directly to cancer cells through monoclonal antibodies, with the objective of improving efficacy while limiting systemic toxicity.

The company’s principal development programs include Iomab-B, an iodine-131-based radiotherapeutic conditioning agent intended for patients with relapsed or refractory acute myeloid leukemia undergoing bone marrow transplant, and Actimab-A, a CD33-targeting radiotherapy candidate being evaluated in combination with other therapeutic regimens. Actinium has also expanded into alpha-particle radiotherapy platforms through actinium-225-based technologies. Founded in 2000 and headquartered in New York, New York, the company evolved from early-stage radiopharmaceutical research into a publicly traded oncology-focused developer listed on the NYSE American under the ticker ATNM.